Last reviewed · How we verify

NCT04551924

A Trial of HR18034 in Inguinal Hernia Repair

Status unknown Phase 1 Last updated 16 September 2020
What this trial tests

Phase 1 trial testing HR18034 in Inguinal Hernia Repair in 64 participants. Status unknown.

Timeline
1 October 2020
Primary endpoint
30 May 2021
30 May 2021

Quick facts

Lead sponsorJiangsu HengRui Medicine Co., Ltd.
PhasePhase 1
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingquadruple
Primary purposesupportive care
Enrollment64
Start date1 October 2020
Primary completion30 May 2021
Estimated completion30 May 2021
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Jiangsu HengRui Medicine Co., Ltd. — full company profile →

Who can join

Adults 18 to 70, any sex, with Inguinal Hernia Repair. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Phase I, randomized, double-blind, comparator-controlled study to assess the safety, PK, and efficacy of single postsurgical application of HR18034 compared with Naropin®

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of HR18034

Trials testing the same drug.

Other recruiting trials for Inguinal Hernia Repair

Currently open trials in the same condition.

Other Jiangsu HengRui Medicine Co., Ltd. trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04551924.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing